Use of pharmacokinetic data in novel analyses to determine the effect of topical microbicides as preexposure prophylaxis against HIV infection

Journal of Infectious Diseases

Volumn 213, Issue 3, 2016, Pages 329-331

  Vermund, Sten H ^a   Walker, A Sarah ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

biostatistical methods; clinical trials; HIV; microbicide; pharmacokinetics; pre exposure prophylaxis; tenofovir

Indexed keywords

MICROBICIDE; PLACEBO; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE;

DRUG BLOOD LEVEL; EXPOSURE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTENTION TO TREAT ANALYSIS; MEDICAL LITERATURE; MEDICATION COMPLIANCE; NOTE; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL BEHAVIOR; SEXUAL EXPOSURE; HIV INFECTIONS; STATISTICS AND NUMERICAL DATA;

ANTI-HIV AGENTS; EMTRICITABINE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; TENOFOVIR;

EID: 84960413951     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv336     Document Type: Note

References (27)

1. Karim QA, Karim SSA, Frohlich JA,. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
2. Grant RM, Lama JR, Anderson PL,. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-99.
3. Thigpen MC, Kebaabetswe PM, Paxton LA,. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367: 423-34.
4. Baeten JM, Donnell D, Ndase P,. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
5. Van Damme L, Corneli A, Ahmed K,. et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367: 411-22.
6. Marrazzo JM, Ramjee G, Richardson BA,. et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372: 509-18.
7. Cottrell ML, Yang KH, Prince HMA,. et al. Predicting effective Truvada PrEP dosing strategies with a novel PK-PD model incorporating tissue active metabolites and endogenous nucleotides (EN). In: HIV Research for Prevention, Cape Town, South Africa, 28-31 October 2014.
8. Karim SSA, Kashuba ADM, Werner L,. et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378: 279-81.
9. Anderson PL, Glidden DV, Liu A,. et al. Emtricitabine-Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4: 151ra125.
10. Dai JY, Gilbert PB, Hughes JP,. et al. Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration. Am J Epi 2013; 177: 256-63.
11. Prentice RL. A case-cohort design for epidemiological cohort studies and disease prevention trials. Biometrika 1986; 73: 1-11.
12. Nair G, Balkus JE, Marrazzo JM,. et al. Baseline predictors of HIV-1 acquisition among women participating in MTN-003 (VOICE). Presented at: 21th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2014.
13. Dai JY, Gilbert PB, Masse BR. Partially hidden Markov model for time-varying principal stratification in HIV prevention trials. J Am Stat Assoc 2012; 107: 52-65.
14. Henan MA. The hazards of hazard ratios. Epidemiology 2010; 21: 13-5.
15. Flanders WD, Greenland S. Analytic methods for two-stage case-control studies and other stratified designs. Stat Med 1991; 10: 739-47.
16. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Stat Med 1991; 10: 45-52.
17. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91: 444-55.
18. Follmann DA. On the effect of treatment among would-be treatment compliers: an analysis of the Multiple Risk Factor Intervention Trial. J Am Stat Assoc 2000; 95: 1101-9.
19. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol 1974; 66: 688-701.
20. Rubin DB. Bayesian inference for causal effects: the role of randomization. Ann Stat 1978; 6: 34-58.
21. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002; 58: 21-9.
22. Hendrix CW, Chen BA, Guddera V,. et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013; 8: e55103.
23. Hendrix CW, Andrade A, Kashuba AD,. et al. Tenofovir-emtricitabine directly observed dosing: 100% adherence concentrations (HPTN 066) [abstract 104]. Presented at: 21st Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2014
24. Hernan MA, Hernadez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15: 615-25.
25. Marrazzo J, Rabe L, Kelly C,. et al. Association of tenofovir (TFV) detection with reduced risk of herpes simplex virus type-2 (HSV-2) acquisition in the VOICE (MTN 003) study. Presented at: HIV Research for Prevention, Cape Town, South Africa, 28-31 October 2014.
26. Rees H, Delany-Moretlwe S, Baron D,. et al. FACTS 001 phase III trial of pericoital Tenofovir 1%gel for HIV prevention in women [abstract 26LB]. Presented at: Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 2015.
27. Louissaint NA, Cao YJ, Skipper PL,. et al. Single dose pharmacokinetics of oral tenofovir in Plasma, peripheral blood mononuclear cells, colonic and vaginal tissue. AIDS Res Hum Retroviruses 2013; 29: 1443-50.